New arbitration full of upsides for Genmab, says analyst
Sydbank Senior Analyst Søren Løntoft Hansen says that there are many upsides and few downsides to Genmab’s decision to initiate new arbitration against Janssen.
by marketwire, translated by catherine brett
After losing a royalties case against its partner Janssen Biotech in April, Genmab has commenced new arbitration concerning Darzalex Faspro.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab CEO on royalties defeat: "I'm sad and disappointed"
For subscribers
Genmab throws in the towel – won't contest royalties ruling
For subscribers
.jpg&w=384&q=75)
